OBJECTIVE: To investigate the safety, efficacy and long-term patency of parallel shunts (PS) in the management of the transjugular intrahepatic portosystemic shunt (TIPS) dysfunction. MATERIALS AND METHODS: Between March 2007 and October 2010, 18 patients (13 men and 5 women) who underwent TIPS revision with the creation of PS were evaluated retrospectively. In the first 10 patients, a 10-mm-diameter Wallgraft endoprosthesis was deployed; in the latter 8 patients, an 8-mm-diameter Fluency endoprosthesis was deployed. RESULTS: The creation of PS was technically successful in all patients. The mean ± standard deviation portosystemic pressure gradient before and after the procedure was 25.5 ± 7.3 mm Hg (range, 16-37 mm Hg) and 10.9 ± 2.3 mm Hg (range, 7-16 mm Hg), respectively. The duration of follow-up was 16.7 ± 10.8 months (range, 6-42 months). The primary shunt patency rates at 12 months after the creation of PS was 70% with Wallgraft endoprostheses and 87.5% with Fluency endoprostheses. CONCLUSION: TIPS revision with the creation of PS is a safe, effective and durable method for treating shunt dysfunction.
OBJECTIVE: To investigate the safety, efficacy and long-term patency of parallel shunts (PS) in the management of the transjugular intrahepatic portosystemic shunt (TIPS) dysfunction. MATERIALS AND METHODS: Between March 2007 and October 2010, 18 patients (13 men and 5 women) who underwent TIPS revision with the creation of PS were evaluated retrospectively. In the first 10 patients, a 10-mm-diameter Wallgraft endoprosthesis was deployed; in the latter 8 patients, an 8-mm-diameter Fluency endoprosthesis was deployed. RESULTS: The creation of PS was technically successful in all patients. The mean ± standard deviation portosystemic pressure gradient before and after the procedure was 25.5 ± 7.3 mm Hg (range, 16-37 mm Hg) and 10.9 ± 2.3 mm Hg (range, 7-16 mm Hg), respectively. The duration of follow-up was 16.7 ± 10.8 months (range, 6-42 months). The primary shunt patency rates at 12 months after the creation of PS was 70% with Wallgraft endoprostheses and 87.5% with Fluency endoprostheses. CONCLUSION: TIPS revision with the creation of PS is a safe, effective and durable method for treating shunt dysfunction.
Authors: Manfred Cejna; Markus Peck-Radosavljevic; Siegfried Thurnher; Maria Schoder; Thomas Rand; Bernhard Angermayr; Johannes Lammer Journal: Cardiovasc Intervent Radiol Date: 2002-03-23 Impact factor: 2.740
Authors: Christophe Bureau; Juan Carlos Garcia-Pagan; Philippe Otal; Gilles Pomier-Layrargues; Valérie Chabbert; Carlos Cortez; Pierre Perreault; Jean Marie Péron; Juan G Abraldes; Louis Bouchard; José Ignacio Bilbao; Jaume Bosch; Hervé Rousseau; Jean Pierre Vinel Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Z J Haskal; M J Pentecost; M C Soulen; R D Shlansky-Goldberg; R A Baum; C Cope Journal: AJR Am J Roentgenol Date: 1994-08 Impact factor: 3.959
Authors: A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum Journal: N Engl J Med Date: 1995-05-04 Impact factor: 91.245
Authors: M Rössle; K Haag; A Ochs; M Sellinger; G Nöldge; J M Perarnau; E Berger; U Blum; A Gabelmann; K Hauenstein Journal: N Engl J Med Date: 1994-01-20 Impact factor: 91.245